布加替尼获批为克唑替尼耐药、alk阳性NSCLC患者提供了额外的治疗选择

{"title":"布加替尼获批为克唑替尼耐药、alk阳性NSCLC患者提供了额外的治疗选择","authors":"J. D. Lartigue","doi":"10.12788/JCSO.0380","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":75058,"journal":{"name":"The Journal of community and supportive oncology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Brigatinib approval yields additional treatment options for crizotinib-resistant, ALK-positive NSCLC patients\",\"authors\":\"J. D. Lartigue\",\"doi\":\"10.12788/JCSO.0380\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":75058,\"journal\":{\"name\":\"The Journal of community and supportive oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of community and supportive oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12788/JCSO.0380\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of community and supportive oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12788/JCSO.0380","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}